News

Cytokinetics and Astellas Expand Development Collaboration Of Skeletal Muscle Activators To Treat Muscular Atrophy, Other Neuromuscular Indications

South San Francisco based Cytokinetics, Incorporated and Astellas Pharma Inc. of Tokyo, Japan, have announced amendments expanding their research collaboration alliance for development and commercialization of skeletal muscle activators. The two companies have been cooperating on research and development efforts, the objective being to…

First Dosing of SMA1 Patient in Gene Transfer Trial’s Intermediate Cohort Begins

Dallas-based biotechnology company AveXis, Inc. announced yesterday that they have successfully dosed the first patient in the intermediate cohort of their Gene Transfer Clinical Trial for chariSM A™ for Spinal Muscular Atrophy Type 1. The news comes just days after the company announced on December 5th that the dosing phase in…